Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and.

Published byHanna Arntsen Modified over 5 years ago

Similar presentations

Presentation on theme: "Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and."— Presentation transcript:

1 Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and those with chronic pancreatitis. Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and those with chronic pancreatitis. Each point represents an individual patient and is usually the mean of several sections analyzed. All ducts on each section were counted (on average ∼100 ducts per patient). There are significant differences between these two groups for glucagon (P < 0.005), amylase (P < ), Ki67 (P < ), PDX-1 (P < ), and insulin (P < 0.05). Jenny M. Phillips et al. Diabetes 2007;56: ©2007 by American Diabetes Association

Download ppt "Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and."

Similar presentations

500X 1000X Name the organ from which these slides were prepared.

500X 1000X Name the organ from which these slides were prepared.
GRADING OF REJECTION IN PANCREAS ALLOGRAFTS Are changes needed? Cinthia B. Drachenberg, M.D. University of Maryland School of Medicine Baltimore MD.

GRADING OF REJECTION IN PANCREAS ALLOGRAFTS Are changes needed? Cinthia B. Drachenberg, M.D. University of Maryland School of Medicine Baltimore MD.
Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:
Mean rates of insulin and glucagon delivery from an artificial pancreas at various blood glucose levels. The device was programmed to establish and maintain.

Mean rates of insulin and glucagon delivery from an artificial pancreas at various blood glucose levels. The device was programmed to establish and maintain.
(Copyright © 1977 American Diabetes Association. Marliss EB et al

(Copyright © 1977 American Diabetes Association. Marliss EB et al
Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.

Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.
25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.

Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.
Insulin content of isolated pancreas and islet morphology.

Insulin content of isolated pancreas and islet morphology.
Volume 136, Issue 2, Pages (February 2009)

Volume 136, Issue 2, Pages (February 2009)
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Immunohistochemical analysis.

Immunohistochemical analysis.
Antitumor effects of FF and gemcitabine on two pancreatic PDX models.

Antitumor effects of FF and gemcitabine on two pancreatic PDX models.
Loss of DGKζ and Cbl-b results in a greater percentage of splenic CD8+ T cells with an activated phenotype. Loss of DGKζ and Cbl-b results in a greater.

Loss of DGKζ and Cbl-b results in a greater percentage of splenic CD8+ T cells with an activated phenotype. Loss of DGKζ and Cbl-b results in a greater.
mpJX-594 effects on tumor burden and leukocyte influx.

mpJX-594 effects on tumor burden and leukocyte influx.
Islet mass and β-cell proliferation is decreased in Hhip–/– embryos (Hip1 in figure). Islet mass and β-cell proliferation is decreased in Hhip–/– embryos.

Islet mass and β-cell proliferation is decreased in Hhip–/– embryos (Hip1 in figure). Islet mass and β-cell proliferation is decreased in Hhip–/– embryos.
Expression of the neural stem cell–specific marker nestin in a distinct cell population within pancreatic islets. Expression of the neural stem cell–specific.

Expression of the neural stem cell–specific marker nestin in a distinct cell population within pancreatic islets. Expression of the neural stem cell–specific.

Similar presentations

Ads by Google